基于尿液生物标志物的慢性肾病诊断与监测系统及SGLT2抑制剂的真实世界有效性
基于尿液生物标志物的慢性肾病诊断与监测系统及SGLT2抑制剂恩格列净的预防性治疗
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
研究概览
详细说明
This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.
The project integrates translational and clinical components:
- validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
- evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.
A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.
The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.
Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.
The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Carlos Martínez Salgado, PhD
- 电话号码:+34616129633
- 邮箱:carlosms@usal.es
学习地点
-
-
-
Salamanca、西班牙
- 招聘中
- Hospital Universitario de Salamanca
-
接触:
- Carlos Martínez Salgado, PhD
- 电话号码:+34616129633
- 邮箱:carlosms@usal.es
-
接触:
- Pilar Fraile Gómez, MD, PhD
- 电话号码:+34923291100
- 邮箱:pilarfg@usal.es
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants with chronic kidney disease (CKD) stages 2-4.
描述
Inclusion Criteria:
- ≥18 years old
- Diagnosed with chronic kidney disease (KDIGO stages 2-4)
- Life expectancy ≥12 months
- Available clinical and laboratory data in the electronic medical record
Exclusion Criteria:
- Current or recent renal replacement therapy or kidney transplantation
- End-stage renal disease
- Participation in interventional trials that may affect outcomes
- Allergy or intolerance to SGLT2i (for exposed cohort)
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Empagliflozin Treatment Group
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety. |
Oral empagliflozin (10-25 mg daily) for 12 months |
|
Control group
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in urinary biomarker panel expression (proteomic fingerprint)
大体时间:Baseline, 6 months, 12 months
|
Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels. |
Baseline, 6 months, 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR)
大体时间:Baseline, 6 months, 12 months
|
Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment. |
Baseline, 6 months, 12 months
|
|
Histopathological improvement of renal tissue (animal study)
大体时间:Monthly up to 9 months
|
Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin. |
Monthly up to 9 months
|
|
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
大体时间:From baseline to 12 months
|
Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator. |
From baseline to 12 months
|
|
Change in estimated glomerular filtration rate (eGFR)
大体时间:From baseline to 12 months
|
Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation. |
From baseline to 12 months
|
|
Change in serum creatinine
大体时间:From baselinte to 12 months
|
hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL). |
From baselinte to 12 months
|
|
Change in urinary albumin-to-creatinine ratio
大体时间:From baseline to 12 months
|
Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine). |
From baseline to 12 months
|
|
Change in serum electrolyte levels
大体时间:From baseline to 12 months
|
Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L). |
From baseline to 12 months
|
|
Change in liver function tests
大体时间:From baseline to 12 months
|
Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L). |
From baseline to 12 months
|
|
Change in glycated hemoglobin (HbA1c)
大体时间:From baseline to 12 months.
|
Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%). |
From baseline to 12 months.
|
|
Change in hematological parameters
大体时间:From baseline to 12 months
|
Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing. |
From baseline to 12 months
|
|
Change in blood pressure
大体时间:From baseline to 12 months
|
Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg). |
From baseline to 12 months
|
|
Change in body weight
大体时间:From baseline to 12 months
|
Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg). |
From baseline to 12 months
|
|
Discontinuation due to treatment intolerance
大体时间:From baseline to 12 months
|
Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting. |
From baseline to 12 months
|
合作者和调查者
调查人员
- 首席研究员:Carlos Martínez Salgado, PhD、University of Salamanca
- 首席研究员:Pilar Fraile Gómez, MD, PhD、University of Salamanca
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- PI25/00053
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
IPD 共享时间框架
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
IPD 共享访问标准
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
IPD 共享支持信息类型
- 研究方案
- 树液
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.